Development of tricyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors.

Bioorg Med Chem Lett

Chemical Biology Laboratory, Molecular Discovery Program, Center for Cancer Research, National Cancer Institute-Frederick, National Institutes of Health, Frederick, MD 21702, USA.

Published: May 2011

New tricyclic HIV-1 integrase (IN) inhibitors were prepared that combined structural features of bicyclic pyrimidinones with recently disclosed 4,5-dihydroxy-1H-isoindole-1,3(2H)-diones. This combination resulted in the introduction of a nitrogen into the aryl ring and the addition of a fused third ring to our previously described inhibitors. The resulting analogues showed low micromolar inhibitory potency in in vitro HIV-1 integrase assays, with good selectivity for strand transfer relative to 3'-processing.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085635PMC
http://dx.doi.org/10.1016/j.bmcl.2011.03.047DOI Listing

Publication Analysis

Top Keywords

hiv-1 integrase
12
integrase inhibitors
8
development tricyclic
4
tricyclic hydroxy-1h-pyrrolopyridine-trione
4
hydroxy-1h-pyrrolopyridine-trione hiv-1
4
inhibitors tricyclic
4
tricyclic hiv-1
4
inhibitors prepared
4
prepared combined
4
combined structural
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!